In this study we determined whether oxcarbazepine (OXC) could produce local peripheral antinociceptive effects in a rat model of inflammatory hyperalgesia, and whether adenosine receptors were involved. When coadministered with the pro-inflammatory compound concanavalin A, OXC (1000-3000 nmol/paw) caused a significant dose- and time-dependent anti-hyperalgesia. Caffeine (1000-1500 nmol/paw), a nonselective adenosine receptor antagonist, as well as 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) (10-30 nmol/paw), a selective A, receptor antagonist, coadministered with OXC, significantly depressed its anti-hyperalgesic effect. Drugs injected into the contralateral hind paw did not produce significant effects. These results indicate that OXC produces local peripheral anti-hyperalgesic effects, which is mediated via peripheral A, receptors.
TY - JOUR
AU - Tomić, Maja
AU - Vučković, Sonja M.
AU - Stepanović-Petrović, Radica
AU - Ugrešić, Nenad
AU - Prostran, Milica
AU - Bošković, Bogdan
PY - 2006
UR - http://farfar.pharmacy.bg.ac.rs/handle/123456789/858
AB - In this study we determined whether oxcarbazepine (OXC) could produce local peripheral antinociceptive effects in a rat model of inflammatory hyperalgesia, and whether adenosine receptors were involved. When coadministered with the pro-inflammatory compound concanavalin A, OXC (1000-3000 nmol/paw) caused a significant dose- and time-dependent anti-hyperalgesia. Caffeine (1000-1500 nmol/paw), a nonselective adenosine receptor antagonist, as well as 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) (10-30 nmol/paw), a selective A, receptor antagonist, coadministered with OXC, significantly depressed its anti-hyperalgesic effect. Drugs injected into the contralateral hind paw did not produce significant effects. These results indicate that OXC produces local peripheral anti-hyperalgesic effects, which is mediated via peripheral A, receptors.
PB - Govi-Verlag Pharmazeutischer Verlag Gmbh, Eschborn
T2 - Pharmazie
T1 - Peripheral anti-hyperalgesia by oxcarbazepine: involvement of adenosine A(1) receptors
VL - 61
IS - 6
SP - 566
EP - 568
UR - conv_1717
ER -
@article{
author = "Tomić, Maja and Vučković, Sonja M. and Stepanović-Petrović, Radica and Ugrešić, Nenad and Prostran, Milica and Bošković, Bogdan",
year = "2006",
abstract = "In this study we determined whether oxcarbazepine (OXC) could produce local peripheral antinociceptive effects in a rat model of inflammatory hyperalgesia, and whether adenosine receptors were involved. When coadministered with the pro-inflammatory compound concanavalin A, OXC (1000-3000 nmol/paw) caused a significant dose- and time-dependent anti-hyperalgesia. Caffeine (1000-1500 nmol/paw), a nonselective adenosine receptor antagonist, as well as 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) (10-30 nmol/paw), a selective A, receptor antagonist, coadministered with OXC, significantly depressed its anti-hyperalgesic effect. Drugs injected into the contralateral hind paw did not produce significant effects. These results indicate that OXC produces local peripheral anti-hyperalgesic effects, which is mediated via peripheral A, receptors.",
publisher = "Govi-Verlag Pharmazeutischer Verlag Gmbh, Eschborn",
journal = "Pharmazie",
title = "Peripheral anti-hyperalgesia by oxcarbazepine: involvement of adenosine A(1) receptors",
volume = "61",
number = "6",
pages = "566-568",
url = "conv_1717"
}
Tomić, M., Vučković, S. M., Stepanović-Petrović, R., Ugrešić, N., Prostran, M.,& Bošković, B.. (2006). Peripheral anti-hyperalgesia by oxcarbazepine: involvement of adenosine A(1) receptors. in Pharmazie
Govi-Verlag Pharmazeutischer Verlag Gmbh, Eschborn., 61(6), 566-568.
conv_1717
Tomić M, Vučković SM, Stepanović-Petrović R, Ugrešić N, Prostran M, Bošković B. Peripheral anti-hyperalgesia by oxcarbazepine: involvement of adenosine A(1) receptors. in Pharmazie. 2006;61(6):566-568.
conv_1717 .
Tomić, Maja, Vučković, Sonja M., Stepanović-Petrović, Radica, Ugrešić, Nenad, Prostran, Milica, Bošković, Bogdan, "Peripheral anti-hyperalgesia by oxcarbazepine: involvement of adenosine A(1) receptors" in Pharmazie, 61, no. 6 (2006):566-568,
conv_1717 .
